- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07938177
Clinical High Risk for Psychosis (CHR) Cohort
A Prospective Longitudinal Cohort Study of Individuals at Clinical High Risk for Psychosis
This study aims to establish a standardized, prospective longitudinal cohort of individuals at clinical high risk for psychosis (CHR) to improve early identification, risk prediction, and outcome assessment of psychotic disorders.
The study will recruit individuals at CHR and healthy controls at Shanghai Mental Health Center. Participants will undergo comprehensive assessments covering clinical symptoms, neurocognitive functioning, psychosocial functioning, and multimodal biological characteristics. Assessments will include standardized clinical interviews and rating scales, neurocognitive tests, natural language sampling, eye-tracking, retinal imaging, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), magnetic resonance imaging (MRI), and biological marker assessments, as applicable.
Individuals at CHR will be followed for up to 36 months, with assessments scheduled at baseline and at 2, 6, 12, 24, and 36 months. Healthy controls will undergo assessments at baseline and at 2 months.
The primary outcome is transition to psychosis during follow-up, determined using standardized clinical criteria. Secondary outcomes include changes in clinical symptoms, psychosocial functioning, cognitive performance, and multimodal biological measures.
By integrating longitudinal clinical and multimodal data, this study seeks to identify risk factors and biomarkers associated with psychosis onset and clinical outcomes, and to develop predictive models that may support earlier identification and personalized preventive strategies.
This is an observational study, and no experimental interventions will be assigned as part of the study protocol.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The study will collect comprehensive clinical, behavioral, neurocognitive, neurophysiological, neuroimaging, ophthalmic, linguistic, and biological data across the following domains:
- Clinical symptoms: psychiatric symptoms and clinical characteristics will be assessed using standardized instruments, including the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Hamilton Depression Rating Scale (HAMD), and Hamilton Anxiety Rating Scale (HAMA).
- Psychosocial functioning: functional outcomes will be evaluated using the Personal and Social Performance Scale (PSP), Global Functioning: Social (GF: Social), Global Functioning: Role (GF: Role), and Global Assessment of Functioning (GAF).
- Neurocognitive functioning: cognitive performance will be assessed using the MATRICS Consensus Cognitive Battery (MCCB), covering domains such as attention, working memory, verbal learning, visual learning, reasoning, and social cognition.
- Natural language and speech analysis: natural language samples will be collected through open-ended interviews to characterize linguistic content, semantic coherence, syntactic organization, and acoustic features. These measures will be investigated as potential markers of psychosis risk and clinical outcomes.
- Eye-tracking assessments: eye-tracking techniques will be used to evaluate oculomotor behavior and visual attention processes. Eye movement parameters obtained from standardized assessment tasks will be investigated as potential behavioral markers associated with psychosis risk.
- Retinal imaging: noninvasive retinal imaging will be performed to assess retinal structural and vascular characteristics, as applicable. Retinal imaging measures will be explored as potential biomarkers associated with clinical symptoms, neurobiological characteristics, and psychosis risk.
- Neuroimaging and neurophysiological measures: brain function and related neurobiological characteristics will be investigated using electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and magnetic resonance imaging (MRI).
- Biological markers: Biological samples will be collected to investigate inflammatory and immune markers, neurotrophic factors, neuroendocrine markers, metabolomic profiles, genomic characteristics, and polygenic risk scores.
- Exploratory biomarker and risk prediction analyses: exploratory analyses will be conducted to identify potential clinical, cognitive, neurophysiological, neuroimaging, ophthalmic, linguistic, and molecular biomarkers associated with transition to psychosis. Candidate predictors will include measures derived from electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), magnetic resonance imaging (MRI), eye-tracking, retinal imaging, natural language and speech analysis, and biological assessments, including inflammatory, neuroendocrine, metabolic, and genetic markers. Associations between candidate predictors and subsequent transition to psychosis will be investigated. Multivariable prediction models will be developed to evaluate whether the integration of multimodal biomarkers improves the prediction of psychosis transition beyond conventional clinical and demographic predictors.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jijun Wang, PhD
- Número de teléfono: +86 21 34773065
- Correo electrónico: jijunwang27@163.com
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200030
- Reclutamiento
- Shanghai Mental Health Center
-
Contacto:
- Jijun Wang, PhD
- Número de teléfono: +86 21 34773065
- Correo electrónico: jijunwang27@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
This prospective observational cohort study will recruit individuals aged 12-35 years at clinical high risk for psychosis (CHR) and healthy controls. CHR participants will be recruited primarily from psychiatric clinical services at Shanghai Mental Health Center and screened using standardized clinical interviews. Healthy controls will be recruited from the community and screened to exclude psychosis-risk syndromes, psychiatric conditions specified in the eligibility criteria, and relevant family history of psychotic disorders.
Participants will be enrolled based on predefined eligibility criteria and informed consent. CHR participants will undergo longitudinal follow-up for up to 36 months, while healthy controls will undergo baseline and 2-month assessments.
Descripción
Inclusion Criteria:
-
1. Clinical High Risk for Psychosis (CHR) group
- Aged 12-35 years, regardless of sex.
- Able to understand the study procedures and provide written informed consent. For participants younger than 18 years, written informed consent must also be obtained from a parent or legal guardian.
- Meets criteria for a clinical high-risk syndrome for psychosis, primarily characterized by the Attenuated Positive Symptom Syndrome (APSS), as assessed using SOPS. Attenuated positive symptoms must have reached the required severity and frequency thresholds within the preceding 12 months.
2. Healthy Control (HC) group
- Aged 12-35 years, regardless of sex.
- Able to understand the study procedures and provide written informed consent. For participants younger than 18 years, written informed consent must be obtained from a parent or legal guardian.
Exclusion Criteria:
-
1. CHR group
- Intellectual disability, defined as an intelligence quotient (IQ) below 70.
- Current or previous central nervous system disease. When necessary, the research team will determine the clinical relevance of a specific neurological condition.
- History of traumatic brain injury, with a score greater than 7 on the traumatic brain injury screening scale.
- History of a treated or untreated psychotic episode.
2. HC group
- Intellectual disability, defined as an intelligence quotient (IQ) below 70.
- Current or previous central nervous system disease. When necessary, the research team will determine the clinical relevance of a specific neurological condition.
- History of traumatic brain injury, with a score greater than 7 on the traumatic brain injury screening scale.
- Meeting criteria for any psychosis-risk syndrome, having a current or past psychotic disorder, or meeting diagnostic criteria for a personality disorder.
- Current use of psychotropic medication for treatment of any condition.
- A family history of a psychotic spectrum disorder in a first-degree relative.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
CHR group
Individuals identified as being at clinical high risk for psychosis based on the Structured Interview for Prodromal Syndromes (SIPS). Participants will undergo comprehensive clinical, cognitive, behavioral, neuroimaging, neurophysiological, ophthalmic, and biological assessments, as applicable. Longitudinal follow-up assessments will be conducted at 2, 6, 12, 24, and 36 months to monitor clinical outcomes, including transition to psychosis. |
|
HC group
Healthy individuals will serve as a comparison group. Participants will undergo standardized clinical, cognitive, behavioral, neuroimaging, neurophysiological, ophthalmic, and biological assessments, as applicable. Assessments will be conducted at baseline and at 2 months to provide reference data for comparison with individuals at clinical high risk for psychosis. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Transition to psychosis within 36 months
Periodo de tiempo: Baseline to 36 months
|
The primary outcome is the occurrence of transition to psychosis among CHR individuals during the 36-month follow-up period. Transition to psychosis will be determined according to the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) criteria by trained clinical evaluators. The outcome will be recorded as whether psychosis transition occurred during follow-up. |
Baseline to 36 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in attenuated psychotic symptom severity
Periodo de tiempo: Baseline and months 2, 6, 12, 24, and 36
|
Attenuated psychotic symptoms will be assessed using SOPS, administered as part of SIPS. The severity of positive symptoms will be evaluated using the SOPS positive symptom subscale (P1-P5), with each item rated from 0 to 6 and a total score ranging from 0 to 30. Higher scores indicate greater symptom severity. Changes from baseline will be evaluated during follow-up. |
Baseline and months 2, 6, 12, 24, and 36
|
|
Change in personal and social functioning
Periodo de tiempo: Baseline and months 2, 6, 12, 24, and 36
|
Personal and social functioning will be assessed using the Personal and Social Performance Scale (PSP). The PSP provides a global score ranging from 1 to 100, with higher scores indicating better functioning. Changes in PSP total scores from baseline will be evaluated during follow-up. |
Baseline and months 2, 6, 12, 24, and 36
|
|
Change in neurocognitive performance
Periodo de tiempo: Baseline and month 2
|
Neurocognitive performance will be assessed using the MATRICS Consensus Cognitive Battery (MCCB). The battery evaluates seven cognitive domains: processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Standardized T-scores will be used to assess cognitive performance, with higher scores indicating better functioning. Changes in cognitive performance from baseline will be evaluated. |
Baseline and month 2
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jijun Wang, Shanghai Mental Health Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2025-SFDL05
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data, including selected clinical, cognitive, neuroimaging, neurophysiological, ophthalmic, linguistic, and biological measures, may be shared with qualified researchers for approved scientific purposes upon reasonable request. Data sharing will be subject to institutional approval, applicable ethics requirements, and execution of appropriate data use agreements. Only the minimum necessary data will be provided through secure, controlled-access mechanisms. Sensitive data, including individual-level genetic information and raw neuroimaging data, will be subject to additional restrictions. Cross-border data transfers will not be permitted without all required regulatory approvals.
Marco de tiempo para compartir IPD
Selected de-identified individual participant data may be made available after completion of relevant analyses, subject to data availability and institutional approval. Access will be granted for a defined period specified in the data use agreement, with renewal subject to further approval.
Criterios de acceso compartido de IPD
Access to de-identified individual participant data will be considered for qualified researchers with scientifically justified proposals. Requests must be reviewed and approved by the principal investigator and the responsible institution, with ethics approval obtained when required. Approved researchers must sign a data use agreement specifying the permitted research purposes, data scope, access duration, confidentiality obligations, and restrictions on re-identification and onward sharing. Only the minimum necessary data will be provided through secure, encrypted transfer. Access to sensitive genetic, neuroimaging, and other regulated data will be subject to additional restrictions. Cross-border data sharing will require all applicable institutional and regulatory approvals.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .